¼ºñ½º »óǰ
¸®¼Ä¡ Á¤º¸
°í°´¼¾ÅÍ
°øÁö»çÇ×
´Ù¿î·Îµå
BONDWEB ½Ã½ºÅÛÀº ²÷ÀÓ¾ø´Â Á¤º¸Çõ½ÅÀ» ÅëÇØ ±ÝÀ¶ ¼±ÁøÈ¿¡ ±â¿©ÇÕ´Ï´Ù.
BONDWEB
º»µåÀ¥Plus
ÃֱٰԽù°
°æÁ¦Á¾ÇÕ´º½º
º¸µµÀÚ·á
½Ã°¡Æò°¡Ç¥
ÁÖ¿ä±Ý¸®
IRS/CRS
½ºÅ©·¦
ÇïÇÁµ¥½ºÅ©
´Ù¿î·Îµå¼¾ÅÍ
°øÁö»çÇ× & ´º½º
ÀÎÀçã±â
ENG
ÀÏÀÚ
ÆÄÀÏ
Á¦¸ñ
±â°ü¸í
08-04
[dz»ê (103140)] Valuation ¸Å·Â ºÎ°¢ À§ÇØ management risk ¿ÏÈ..
»ï¼ºÁõ±Ç
08-04
[È£ÅڽŶó (008770)] È£ÅÚÀº ¸ÅÃâ Áõ°¡, ¸é¼¼´Â ¼öÀͼº °³¼±
»ï¼ºÁõ±Ç
08-04
[F&F (383220)] 2Q26 review: ÀϽÃÀû ºÎÁø, ¹æÇ⼺Àº ±×´ë·Î
»ï¼ºÁõ±Ç
08-04
[´ëÇÑÀ¯È (006650)] 2Q26 review - Àç°íÈ¿°ú Á¦¿Ü ½Ã ÈÇÐ ÈæÀÚ..
»ï¼ºÁõ±Ç
08-04
¹Ì±¹ ¸¶°¨½ÃȲ : ºòÅ×Å© ¼±Àü ÈûÀÔ¾î »ó½Â ¸¶°¨
»ï¼ºÁõ±Ç
08-04
[LGÈÇÐ (051910)] 2Q26 review - ¿¹»óº¸´Ù °ÇÑ ½ÇÀû ½ÃÇö
»ï¼ºÁõ±Ç
08-04
[¿¡ÄÚÇÁ·Îºñ¿¥ (247540)] À¯·´³» ¼öÁÖ¿Í ´ÏÄÌ Á¦·Ã¼Ò °¡µ¿¿¡ °Å´Â..
»ï¼ºÁõ±Ç
08-04
<¿ù°£Àü¸Á - 2026.08> ÄöÆ® ¸ðµ¨ Ãßõ Á¾¸ñ - 2026³â 8¿ù: ½ÃÀå ..
»ï¼ºÁõ±Ç
08-04
<¿ù°£Àü¸Á - 2026.08> Çѱ¹ Áõ½Ã Àü¸Á°ú Àü·«: ¡®26³â 8¿ù: ±Û·Î..
»ï¼ºÁõ±Ç
08-04
[È¿¼ºÁß°ø¾÷ (298040)] ±Þ°ÝÈ÷ ½×¿© °¡´Â ¼öÁÖ
»ï¼ºÁõ±Ç
08-04
[ÇÑÈ¿¡¾î·Î½ºÆäÀ̽º (012450)] ¹ë·ù¿¡ÀÌ¼Ç ¸Å·Â°ú ¸ð¸àÅÒÀ» µÎ·ç..
»ï¼ºÁõ±Ç
08-04
[DL E&C (375500)] 2Q review: Beats expectations once again
»ï¼ºÁõ±Ç
08-04
[Lotte Fine Chemical (004000)] 2Q review; valuation becoming..
»ï¼ºÁõ±Ç
08-04
[Medtech/Cosmetics] Pay attention after 2Q earnings releases
»ï¼ºÁõ±Ç
08-04
[ÆÄ»ý¸Æ¶ô] ¹Ì±¹µµ Áֽļ±¹°½ÃÀå ¿·È´Ù: CME °³º°Áֽļ±¹°½ÃÀå
»ï¼ºÁõ±Ç
Àüü : 608
óÀ½
ÀÌÀü
[1]
[2]
[3]
[4]
[5]
´ÙÀ½
³¡À¸·Î
Ȩ > ¸®¼Ä¡Á¤º¸ >
ÃֱٰԽù°